YARW news

Latest 1 stories · newest Nov 12, 2026

YARW

Yarrow Bioscience completes $172.5M offering and funds Q3 2026 results

Yarrow Bioscience Inc. reported Q3 2026 results, completed a $172.5M public offering extending cash runway to 2030, and announced Phase 2a topline results expected mid-2027.

Offering|Earnings Nov 12, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same YARW feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/YARW/newsSTART FREE